|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1993-6-15
|
|
pubmed:abstractText |
Cisplatin and etoposide combination chemotherapy is the most commonly used regimen for advanced non-small cell lung cancer (NSCLC). 5-Fluorouracil (5-FU) is an agent with little intrinsic activity against NSCLC: However, there is increasing evidence that 5-FU is synergistic with cisplatin and vice versa. In an effort to improve on the traditional chemotherapeutic approach to NSCLC, a treatment regimen consisting of cisplatin, 5-FU, and etoposide (PFE) was developed.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2953-7
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8387871-Adult,
pubmed-meshheading:8387871-Aged,
pubmed-meshheading:8387871-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8387871-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:8387871-Cisplatin,
pubmed-meshheading:8387871-Etoposide,
pubmed-meshheading:8387871-Female,
pubmed-meshheading:8387871-Fluorouracil,
pubmed-meshheading:8387871-Humans,
pubmed-meshheading:8387871-Lung Neoplasms,
pubmed-meshheading:8387871-Male,
pubmed-meshheading:8387871-Middle Aged,
pubmed-meshheading:8387871-Prognosis,
pubmed-meshheading:8387871-Survival Analysis
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer.
|
|
pubmed:affiliation |
Division of Clinical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
